Disconnect between <i>in vitro</i> and <i>in vivo</i> efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma
Mark C. de Gooijer(Manchester Academic Health Science Centre), Olaf van Tellingen(The Netherlands Cancer Institute), Hilal Çolakoğlu(The Netherlands Cancer Institute), Jos H. Beijnen(The Netherlands Cancer Institute), Levi C.M. Buil(Cancer Genomics Centre), Laura E. Kuil(The Netherlands Cancer Institute), Ping Zhang(Tongji University), Ana Maia(The Netherlands Cancer Institute), Ceren H. Çitirikkaya(The Netherlands Cancer Institute), Margarita Espitia-Ballestas(The Netherlands Cancer Institute), Irena Bočkaj(University of Groningen)
Cited by 1
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
|Journal of Clinical Oncology|1993|313